Efficacy and Safety of Suhuang Zhike Capsules in the Treatment of Adult Patients with Cough-Variant Asthma:A Systematic Review
Objective To systematically review the efficacy and safety of Suhuang Zhike Capsules in the treatment of cough-variant asthma(CVA).Methods The randomized controlled trials(RCTs)of Suhuang Zhike Capsules in the treatment of CVA in the PubMed,The Cochrane Library,CBM,CNKI,VIP,WanFang database,and China Clinical Trial Registration Center from their inception to April 1,2023 were searched and screened based on inclusion criteria.The Cochrane 5.2.0 system manual was used to evaluate the quality of the literature,and RevMan 5.4 software was used for statistical analysis.Results A total of 28 studies were included,involving 2 571 patients with CVA,including 1 303 patients in the observation group(treated with Suhuang Zhike Capsules combined with conventional Western medicine)and 1 268 patients in the control group(treated with conventional Western medicine).Meta-analysis results showed that the total treatment effective rate[OR=4.46,95%CI(3.39,5.88),P<0.000 01],and the improvement of peak expiratory flow[MD=10.52,95%CI(9.00,12.04),P<0.000 01],forced expiratory volume in the first second[MD=0.52,95%CI(0.47,0.56),P<0.000 01],cough score[MD=-0.40,95%CI(-0.43,-0.36),P<0.000 01],forced vital capacity[MD=0.54,95%CI(0.49,0.59),P<0.000 01],and interleukin-6[MD=-3.90,95%CI(-4.37,-3.44),P<0.000 01]in the observation group was significantly better than that in the control group.No serious adverse reactions were reported in the two groups,and mild adverse reactions could be relieved without stopping the medication.Conclusion Suhuang Zhike Capsules are effective and safe in the treatment of CVA,which can improve the patients'forced expiratory volume in the first second,cough symptoms,forced vital capacity,and interleukin-6 levels.
国家科技期刊平台
NSTL
万方数据
